

# **Operational Performance Report Month 7**

Trust Board 28<sup>th</sup> November 2019



### **Summary**

| Operational Performance  |   |        |         |         |         |         |         |         |        |       |         |     |
|--|---|--------|---------|---------|---------|---------|---------|---------|--------|-------|---------|-----|
| Metric   | 1 | 「arget | Apr-19  | May-19  | Jun-19  | Jul-19  | Aug-19  | Sep-19  | Oct-19 | Month | Quarter | YTD |
| A&E 4 Hour Performance   | x | 95%    | 68.30%  | 73.08%  | 71.14%  | 73.47%  | 73.63%  | 66.10%  | 64.50% | Ļ     | Ļ       | Ļ   |
| A&E Minor 4 Hour Performance   | x | 97%    | 96.40%  | 97.42%  | 96.79%  | 95.75%  | 95.43%  | 93.27%  | 94.06% | 1     | 1       | Ļ   |
| Cancer 2WW all cancers, Urgent GP Referral                               | x | 93%    | 82.20%  | 80.30%  | 81.70%  | 81.70%  | 85.30%  | 92.70%  |        | 1     | 1       | Ļ   |
| Cancer 2WW Symptomatic Breast  | x | 93%    | 28.00%  | 12.50%  | 15.20%  | 21.00%  | 44.70%  | 91.00%  |        | 1     | 1       | Ļ   |
| Cancer 31-Day Surgery, subsequent treatments                             | 1 | 94%    | 86.49%  | 86.67%  | 97.50%  | 90.00%  | 87.10%  | 94.90%  |        | 1     | Ļ       | Ļ   |
| Cancer 31-Day Drugs, subsequent treatments                               | 1 | 98%    | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |        | 1     | 1       | 1   |
| Cancer 31-Day Diag to treat, all new cancers                             | 1 | 96%    | 97.50%  | 97.90%  | 97.10%  | 97.00%  | 98.20%  | 98.50%  |        | 1     | 1       | 1   |
| Cancer Waiting Times - 62 Day GP Referral                                | x | 85%    | 72.10%  | 74.50%  | 71.60%  | 73.82%  | 73.31%  | 69.40%  |        | Ļ     | Ļ       | Ļ   |
| Cancer Waiting Times - 62 Day Screening                                  | 1 | 90%    | 92.20%  | 82.10%  | 73.70%  | 95.45%  | 98.25%  | 91.70%  |        | Ŧ     | 1       | Ļ   |
| Cancer Waiting Times - 62 Day Upgrade                                    |   |        | 85.60%  | 86.60%  | 86.90%  | 82.32%  | 88.59%  | 85.60%  |        | Ŧ     | Ļ       | Ļ   |
| RTT Performance  | X | 92%    | 87.45%  | 87.83%  | 87.01%  | 85.99%  | 85.77%  | 86.15%  | 85.03% | Ŧ     | Ļ       | Ļ   |
| RTT Volume of Patients on Incomplete Pathways Waiting List               | X | 18,027 | 18,902  | 18,745  | 18,860  | 18,825  | 19,176  | 19,196  | 19,330 | Ţ     | Ļ       | Ļ   |
| RTT Number of Patients over 52 weeks on Incomplete Pathways Waiting List | > | 0      | 0       | 0       | 0       | 0       | 0       | 0       | 0      | ↑     |         |     |
| Waiting Times - Diagnostic Waits <6 weeks                                | 1 | 99%    | 99.17%  | 99.28%  | 99.52%  | 98.76%  | 97.58%  | 97.29%  | 99.36% | 1     | Ļ       | Ļ   |

Please note Cancer Waiting Times - 62 Day Upgrade does not have a national target






#### RTT



# **Elective Activity - RTT 2019/2020 Trajectory**

Please note the SPC graph has been calculated using 24 point, however only 14 points are illustrated



#### Key actions for December :


- Review of urgent and long waiters
- Management of list to minimise short notice cancellations
- Capacity options Quarter 4 to continue to ensure no 52 week
   breaches
- Vanguard in place from mid Dec at PRH and additional beds at RSH from mid December

#### Key risks:

- Bed gap will impact on DSU usage if emergency demand continues.
- Achievement of March 2020 waiting list size to be same as March 2019
- Staffing gaps within theatre teams and consultant anaesthetists
- Impact of pension/tax restrictions on waiting list size.
- Greater than 52 week waiters




### **RTT Waiting List Size Projection**



The total waiting list size in October was 19330 against the operational plan trajectory at this point of 18227. The requirement is to bring the March 2020 position back in line with the March 2019 level (18,064)



### **RTT Breakdown**



|                        | V      | Vaiting List | Size   | P      | erformance |        |
|------------------------|--------|--------------|--------|--------|------------|--------|
|                        | Oct-18 | Oct-19       | % Var  | Oct-18 | Oct-19     | % Var  |
| Ophthalmology          | 2646   | 2814         | 6.3%   | 93.0%  | 93.0%      | 0.0%   |
| General Surgery        | 2735   | 2768         | 1.2%   | 93.7%  | 87.8%      | -6.2%  |
| Ear nose & throat      | 2239   | 2521         | 12.6%  | 95.8%  | 85.3%      | -10.9% |
| Oral Surgery           | 1059   | 1792         | 69.2%  | 90.5%  | 62.6%      | -30.8% |
| Urology                | 1647   | 1732         | 5.2%   | 87.6%  | 79.3%      | -9.5%  |
| Gynaecology            | 1423   | 1416         | -0.5%  | 92.3%  | 89.3%      | -3.3%  |
| Gastroenterology       | 1376   | 1344         | -2.3%  | 98.1%  | 93.9%      | -4.3%  |
| Other                  | 976    | 1024         | 4.9%   | 95.5%  | 90.4%      | -5.3%  |
| Cardiology             | 622    | 982          | 57.9%  | 93.4%  | 77.0%      | -17.6% |
| Respiratory Medicine   | 596    | 786          | 31.9%  | 85.7%  | 76.1%      | -11.3% |
| Dermatology            | 649    | 765          | 17.9%  | 96.6%  | 90.8%      | -6.0%  |
| General Medicine       | 608    | 637          | 4.8%   | 98.8%  | 91.8%      | -7.1%  |
| Trauma & Orthopaedics  | 436    | 449          | 3.0%   | 97.0%  | 81.7%      | -15.8% |
| Geriatric Medicine     | 284    | 266          | -6.3%  | 95.4%  | 96.2%      | 0.9%   |
| Cardiothoracic Surgery | 11     | 33           | 200.0% | 100.0% | 97.0%      | -3.0%  |
| Neurology              | 1      | 1            | 0.0%   | 100.0% | 100.0%     | 0.0%   |






### **Diagnostics**



### **Diagnostics Waiting Time**



#### **Key Actions:**

 Continue to improve endoscopy backlog

#### **Key Risks:**

 Recovery of Endoscopy position and maintaining the Radiology position

|                           |          | Jun-19    | •           | Jul-19   |           | Aug-19      |          |           | Sep-19      |          |           | Oct-19      |          |           |             |
|---------------------------|----------|-----------|-------------|----------|-----------|-------------|----------|-----------|-------------|----------|-----------|-------------|----------|-----------|-------------|
|                           | Total WL | Over 6wks | Performance |
| Imaging                   | 4775     | 25        | 99.48%      | 4796     | 69        | 98.56%      | 4696     | 47        | 99.00%      | 5345     | 67        | 98.75%      | 6014     | 24        | 99.60%      |
| Physiological Measurement | 522      | 1         | 99.81%      | 532      | 2         | 99.62%      | 642      | 1         | 99.84%      | 616      | 3         | 99.51%      | 336      | 6         | 98.21%      |
| Endoscopy                 | 723      | 3         | 99.59%      | 736      | 4         | 99.46%      | 737      | 99        | 86.57%      | 676      | 110       | 83.73%      | 790      | 16        | 97.97%      |
| Total                     | 6020     | 29        | 99.5%       | 6064     | 75        | 98.8%       | 6075     | 147       | 97.58%      | 6637     | 180       | 97.29%      | 7140     | 46        | 99.36%      |






### Cancer



### Cancer 2 Week Wait Trajectory 2019/20



#### October 2019 predicted figures

| Cancer Waiting Times - 2 Week Wait      | Apr-19 | May-19 | Jun-19 | Jul-19 | Aug-19 | Sep-19 | Oct-19 | Nov-19 | Dec-19 | Jan-20 | Feb-20 | Mar-20 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Trajectory Number Seen < 2 Wks          | 1,923  | 2,216  | 2,075  | 2,177  | 2,143  | 2,009  | 2,342  | 2,290  | 2,016  | 2,112  | 2,203  | 2,287  |
| Trajectory Total Number Seen            | 2,095  | 2,388  | 2,238  | 2,322  | 2,288  | 2,154  | 2,487  | 2,435  | 2,161  | 2,257  | 2,348  | 2,432  |
| Trajectory Performance % (93% standard) | 91.8%  | 92.8%  | 92.7%  | 93.8%  | 93.7%  | 93.3%  | 94.2%  | 94.0%  | 93.3%  | 93.6%  | 93.8%  | 94.0%  |
| Actual Number Seen < 2 Wks              | 1905   | 1843   | 1914   | 2073   | 1980   | 2083   | 2338   |        |        |        |        |        |
| Actual Total Number Seen                | 2317   | 2296   | 2344   | 2536   | 2322   | 2248   | 2527   |        |        |        |        |        |
| Actual Performance % (93% standard)     | 82.2%  | 80.3%  | 81.7%  | 81.7%  | 85.3%  | 92.7%  | 92.5%  |        |        |        |        |        |


#### **Key Actions December 2019**

- Continue to introduce telephone booking as preferential booking format for additional specialties.
- The use of the electronic triage function on ERS to further speed up the triage process for 2WW referrals

#### **Key Risks**

- Delay in GMC registration for consultant radiologist, will now be approved by March 2020.
- Capacity within lung cancer team to see all 2 week wait in target.
- Pension tax impacting on performance.


### **Cancer Performance 31 Day Wait Summary**



#### October 2019 predicted figures

| Cancer Waiting Times - 31 Day First Treatment | Apr-19 | May-19 | Jun-19 | Jul-19 | Aug-19 | Sep-19 | Oct-19 | Nov-19 | Dec-19 | Jan-20 | Feb-20 | Mar-20 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Number Treated < 31 Days                      | 248    | 267    | 280    | 262    | 280    | 270    | 273    | 275    | 249    | 260    | 254    | 268    |
| Total Number Seen                             | 250    | 269    | 283    | 264    | 282    | 274    | 273    | 277    | 253    | 262    | 255    | 269    |
| Performance % (96% standard)                  | 99.2%  | 99.3%  | 98.9%  | 99.2%  | 99.3%  | 98.5%  | 100.0% | 99.3%  | 98.4%  | 99.2%  | 99.6%  | 99.6%  |
| Number Treated < 31 Days                      | 272    | 274    | 237    | 290    | 277    | 269    | 264    |        |        |        |        |        |
| Total Number Seen                             | 279    | 280    | 244    | 299    | 282    | 273    | 271    |        |        |        |        |        |
| Performance % (96% standard)                  | 97.5%  | 97.9%  | 97.1%  | 97.0%  | 98.2%  | 98.5%  | 97.4%  |        |        |        |        |        |

#### **Cancer 62 Day GP Referral**



#### October 2019 predicted figures

| Cancer Waiting Times - 62 Day GP Referral   | Apr-19 | May-19 | Jun-19 | Jul-19 | Aug-19 | Sep-19 | Oct-19 | Nov-19 | Dec-19 | Jan-20 | Feb-20 | Mar-20 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Ongoing Forecast - Number Treated < 62 Days | 106    | 122    | 132    | 115    | 142    | 87     | 94     | 123    | 118    | 123    | 103    | 111    |
| Total Number Seen                           | 141    | 154    | 162    | 141    | 168    | 129    | 133    | 162    | 153    | 161    | 129    | 133    |
| Performance % (85% standard)                | 75.1%  | 79.2%  | 81.4%  | 81.5%  | 84.5%  | 67.7%  | 70.9%  | 76.2%  | 77.1%  | 76.4%  | 80.2%  | 83.5%  |
| Number Treated < 62 Days                    | 114.5  | 122    | 109.5  | 125.5  | 103    | 100    | 117.5  |        |        |        |        |        |
| Total Number Seen                           | 158    | 162.5  | 153    | 170    | 140.5  | 144    | 155.5  |        |        |        |        |        |
| Performance % (85% standard)                | 72.5%  | 75.1%  | 71.6%  | 73.8%  | 73.3%  | 69.4%  | 75.6%  |        |        |        |        |        |


#### **Key Actions**

- Introduction of weekly Cancer Assurance and Performance meetings
- Capacity review
- NHSI led improvement planning

#### Key Risks

- Urology capacity due to workforce gaps .
- Anaesthetic capacity to support additional lists
- Impact of 2ww lung capacity on 62 day performance.

### **Cancer Performance By Tumour – Sept 19**



#### 2 Week Wait:


There are currently significant delays for Oncology appointments for certain specialties (up to 3 weeks or more) as a result of capacity issues.

#### 62 Day % Meeting National Standard 100 90 80 70 60 50 40 30 20 10 0 Skin Other Breast Lower GI Urology Lung 62 Day % meeting standard ······ Target

#### 62 Day:

Current prediction for October-19 is at 75.5%. The reduction in performance is as a result of clearing the backlog of patients waiting over 62days.

### 104 day breaches



The following patients received their first definitive treatment for cancer after 104 days in September 2019 (the target for referral to treatment being 62 days):-

- 1 x Breast (122 days) Diagnosis delayed for medical reasons pathway delayed as patient in hospital for 3 weeks. Patient also failed to attend an OPA.
- 1 x Colorectal (115 days) Patient choice.
- 1 x Colorectal (108 days) Complex diagnostic pathway.
- 1 x Colorectal (110 days) Complex pathway.
- 1 x Lung (166 days) Diagnosis delayed for medical reasons.
- 1 x Lung (151 days) Delayed pathway. First OPA day 21. Patient required review and investigation in other specialty.
- 1 x Lung (175 days) Complex pathway. Patient required review in x2 specialties prior to referral to Lung.
- 1 x UGI (116 days) Capacity issues in Radiology led to MDT discussion deferred. OPA Surgeon delayed due to no surgeon being available at SATH one week.

- 1 x UGI (147 days) Complex pathway / patient choice. Multiple and repeat investigations needed as patient did not wish to progress to surgery.
- 1 x UGI (106 days) Complex pathway investigations required in other specialty.
- 1 x Urology (187 days) Delay for diagnostics/MDT discussion. 23 days for CT. Patient choice to delay investigation.
- 1 x Urology (105 days) Diagnosis delayed for medical reasons patient had UTI delaying investigations for 3 weeks.
- 1 x Urology (133 days) Medical delay.
- 1 x Urology (105 days) Complex diagnostic pathway / delay for diagnostics.
- 1 x Urology (107 days) Complex Pathway.
- 1 x Urology (107 days) Delay for diagnostics / elective capacity inadequate. One surgeon
  only performs this surgery at SaTH.



# **Urgent Care Update**



# **A&E Attendances (excluding MIU)**

The Shrewsbury & Telford Hospitals NHS Trust - A&E Attendances (no MIU) The Shrewsbury & Telford Hospitals NHS Trust - A&E Breaches 15.000 5,000 14,000 4,500 13,000 4,000 12,000 3,500 s 11,000 3,000 Breache 2,500 dan 10,000 9,000 2,000 8,000 1,500 7,000 1,000 6,000 500 5,000 and the set of the set ec.2018 A&F Attendances (no MIU) Rising or Falling Trend A&F Breaches Points above and below mean Oct-19 Trajectory: Oct-19 Trajectory: Oct-19 Actual: 12.399 11.828 Variance to Trajectory 571 Oct-19 Actual: 4.400 2.482 Variance to Trajectory 1,918

Please note the SPC graph has been calculated using 24 point, however only 14 points are illustrated


The following recovery actions are included within the trajectory:

- Reduction in 4 4 1/2 hour breaches validation process
- Reduction in 4 4 1/2 hour breaches in hours/ ED owned
- Utilisation of CDU
- Paediatric patients streamed/triaged direct to PAU
- Referral to Fracture clinic from ED



- Improved ED systems and processes
- Adhering to Internal Professional Standards

## A&E Performance – (excluding MIU)




Please note the SPC graph has been calculated using 24 point, however only 14 points are illustrated

| Accident and Emergency Performance            | Apr-19 | May-19 | Jun-19 | Jul-19 | Aug-19 | Sep-19 | Oct-19 | Nov-19 | Dec-19 | Jan-20 | Feb-20 | Mar-20 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Trajectory A&E - Total Patients               | 12243  | 12063  | 11986  | 12278  | 11658  | 11387  | 11828  | 11281  | 11424  | 11583  | 10942  | 12305  |
| Trajectory A&E - >4 hour wait                 | 3881   | 2482   | 2156   | 2196   | 1753   | 2164   | 2170   | 2169   | 2236   | 2120   | 1800   | 1843   |
| Trajectory A&E - Performance % (95% standard) | 68.3%  | 79.4%  | 82.0%  | 82.1%  | 85.0%  | 81.0%  | 81.7%  | 80.8%  | 80.4%  | 81.7%  | 83.5%  | 85.0%  |
| Actual A&E - Total Patients                   | 12243  | 12383  | 12225  | 13441  | 12574  | 12623  | 12399  | _      |        |        |        |        |
| Actual A&E - >4 hour wait                     | 3881   | 3332   | 3528   | 3566   | 3375   | 4282   | 4400   |        |        |        |        |        |
| Actual A&E - Performance % (95% standard)     | 68.3%  | 73.1%  | 71.1%  | 73.5%  | 73.2%  | 66.1%  | 64.5%  |        |        |        |        |        |



### **Ambulance arrivals and handover delays**

Please note the SPC graph has been calculated using 24 point, however only 14 points are illustrated




#### Handover breaches by time band for October 2019:

Please note based on WMAS Figures

|        |            | Trajectory |         |            | Actual     |         | % Varia    | ance Trajectory vs | Actual  |
|--------|------------|------------|---------|------------|------------|---------|------------|--------------------|---------|
|        | 15-30 mins | 30-60 mins | >60mins | 15-30 mins | 30-60 mins | >60mins | 15-30 mins | 30-60 mins         | >60mins |
| Oct-19 | 2286       | 734        | 172     | 1596       | 892        | 217     | -30.18%    | 21.53%             | 26.16%  |


Continuing to work with system wide handover group and West Midlands Ambulance Service to reduce overall handover delays

### **12 Hour Breaches**




The Trust has experience a substantial increase in 12 hour delays from decision to admit from A&E. October 2019 saw 39 more breaches compared to the same period last year.


### Discharges



- Pre 12 discharges below national average.
- Workforce gaps are impacting on improvement.




### **Stranded Patients over all position**



Improvement in stranded patients (>6 LOS) has been maintained by both Care Groups (Scheduled and Unscheduled)

### **Super Stranded Patient**



The Trust worked towards achieving the 23% NHSI target in 2018/19, it is now working towards the 40% reduction set by NHSi



# **Finance Report Month 7**



### Finance Overview 2019/20

#### Income & Expenditure Position Month 7 Year to Date

The Trust has a planned deficit of £8.826m for the period April –October 2019. (Annual Plan £17.351m deficit). Actual Deficit reported is £11.735m, £2.909m above planned levels

Income £11.1m overachieved, predominately within

- non elective activity £2.573m (3.6%) above plan.
- A&E activity £0.734m (6.4%) above plan.
- Non Elective Other (Maternity) £1.0m
- Additional £0.3m for additional posts funded externally including Health Education England.
- Phased income adjustment from both local CCGs of £2.4m.
- Deferred Income and Education income release £0.4m.
- Readmission income of £1.480m.
- FIT Monies of £0.613m.

Pay £6.3m overspent, as a result of an overspend on agency costs of £4.2m and non delivery of CIP of £1.5m.

**Non Pay (excl. pass throughs) £9.2m,** additional consultancy fees £0.9m; diagnostic reporting £1.2m and non delivery of CIP of £3.2m; additional costs of clinical waste and other estate costs £1.4m; Clinical supplies £0.5m; RN recruitment £0.3m.

Balance Sheet Review £1.2m Release of Balance Sheet items transacted in the Month 3 financial position.

|  | Annual    |           | YTD       |          |
|--|-----------|-----------|-----------|----------|
|  | NHSI Plan | Plan      | Actual    | Variance |
|  | £000s     | £000s     | £000s     | £000s    |
|  |           |           |           |          |
| Income   | 345,477   | 201,383   | 212,496   | 11,113   |
| Income for pass through costs (Excluded medicines and devices) | 33,382    | 19,525    | 19,339    | (186)    |
| Pay  | (273,760) | (157,753) | (163,306) | (5,553)  |
| Non-Pay & Reserves   | (76,109)  | (45,207)  | (54,384)  | (9,177)  |
| Non-pay pass through costs                                     | (33,382)  | (19,525)  | (19,339)  | 186      |
| Reserves   | 1,200     | 700       | 1,200     | 500      |
| Total expenditure  | (382,051) | (221,785) | (235,829) | (14,044) |
| EBITDA   | (3,192)   | (877)     | (3,994)   | (3,117)  |
| Finance Costs  | (14,159)  | (7,949)   | (7,741)   | 208      |
| Surplus/(deficit) against Control Total pre Support            | (17,351)  | (8,826)   | (11,735)  | (2,909)  |
|  |           |           |           |          |
| Provider Support   | 17,351    | 8,444     | 8,444     | C        |
| Surplus/(deficit) against Control Total post PSF               | о         | (382)     | (3,291)   | (2,909)  |

**Cash** If the Trust achieves the planned breakeven position, it will be eligible for funding totalling £12.593m in respect of conditional PSF/FRF funding. It is projected that the minimum cash balance of £1.700m will be achieved.

However if the Trust does not achieve financial plan, PSF and FRF funding will not be received for Quarters 3 and 4 resulting in shortfall in income of £8.138m. The projected cashflow is based on the revised forecast projection of deficit of £19.734m, with cash benefit in 2019/20 in respect of receipt of PSF funding relating to 2018/19 (£4.5m)

It is projected that the Trust will require external cash support of  $\pm 15.327m$ .

The Trust will receive cash support in lieu of conditional funding of £2.520m in November and has requested £3.402m to be received in December. This support is included in the forecast. This is repayable on receipt of conditional income funding.

**Capital** The total (purchased and donated) Internally Generated Capital Resource Limit (CRL) for 2019/20 is now £11.618 m. At Month 07, only £1.657m remains uncommitted - £0.152m in Corporate Contingency; £0.751m within the delegated reserve fund; £0.749m within the general uncommitted reserve and £0.005m yet to be committed in agreed schemes. The Trust is currently £0.351m overcommitted (after allocation for FIT equipment) whilst awaiting confirmation of receipt of £0.441m funding from HSLI funding for Data Warehouse. (Business case to be submitted in November) The formal application is currently being finalised. Trust has received confirmation of success of emergency capital loan funding £1.622m for fire safety in the Copthorne building. The Trust has been successful in receiving additional capital funding of £5.5m for additional capacity (£4.0m Modular Building at PRH and £1.5m for additional beds at RSH & PRH) as reported at last Board meeting).

### **Income & Expenditure – In Month**

|  | Annual    |          | In Month |          |  |  |  |
|--|-----------|----------|----------|----------|--|--|--|
|  | NHSI Plan | Plan     | Actual   | Variance |  |  |  |
|  | £000s     | £000s    | £000s    | £000s    |  |  |  |
|  |           |          |          |          |  |  |  |
| Income   | 345,477   | 30,303   | 30,311   | 8        |  |  |  |
| Income for pass through costs (Excluded medicines and devices) | 33,382    | 2,945    | 3,080    | 135      |  |  |  |
| Рау  | (273,760) | (22,396) | (24,002) | (1,606)  |  |  |  |
| Non-Pay & Reserves   | (76,109)  | (6,898)  | (8,254)  | (1,356)  |  |  |  |
| Non-pay pass through costs                                     | (33,382)  | (2,945)  | (3,080)  | (135)    |  |  |  |
| Reserves   | 1,200     |          |          | 0        |  |  |  |
| Total expenditure  | (382,051) | (32,239) | (35,336) | (3,097)  |  |  |  |
| EBITDA   | (3,192)   | 1,009    | (1,945)  | (2,954)  |  |  |  |
| Finance Costs  | (14,159)  | (1,141)  | (1,104)  | 37       |  |  |  |
| Surplus/(deficit) against Control Total pre Support            | (17,351)  | (132)    | (3,049)  | (2,917)  |  |  |  |
|  |           |          |          |          |  |  |  |
| Provider Support   | 17,351    | 1,656    | 1,656    | 0        |  |  |  |
| Surplus/(deficit) against Control Total post PSF               | о         | 1,524    | (1,393)  | (2,917)  |  |  |  |

#### **Key Message**

- In Month the Trust is £2.917m above control total.
- Income £0.143m above plan
- Phased Income adjustment
- Reduction in the month of £0.5m, the cumulative position is now £2.4m from £2.9m
- Income continues to over-deliver against plan predominately within non-electives.

#### • Pay £1.6m above plan

- Non-delivery of CIP (£0.1m)
- Agency usage (£0.9m) above plan
- Increased levels of substantive recruitment across all staff groups (£0.1m)
- ED RN volume increased above business plan (£0.1m).

#### • Non Pay £1.4m

- Non-delivery of CIP (£0.5m)
- Diagnostic reporting (£0.2m)
- Clinical Waste (£0.1m)
- Consultancy fees (£0.1m)
- Maintenance contracts (£0.1m)
- Overseas Nursing Recruitment Fees (£0.1m).



## **Normalised Income and Expenditure**

|   | Month 1  | Month 2  | Month 3          | Month 4  | Month 5  | Month 6  | Month 7  | Total     |
|---|----------|----------|------------------|----------|----------|----------|----------|-----------|
|   | £000s    | £000s    | £000s            | £000s    | £000s    | £000s    | £000s    | £000s     |
| Income (excluding PSF & Passthrough)                | 29,238   | 28,800   | 31,057           | 30,014   | 30,312   | 32,764   | 30,311   | 212,496   |
| Passthrough Income (excluded medicines and devices) | 2,363    | 2,829    | <i>2,7</i> 35    | 3,028    | 2,646    | 2,658    | 3,080    | 19,339    |
| Income finalisation phasing                         | (566)    | 926      | 105              | 640      | (1,009)  | 186      | (282)    | 0         |
| Рау   | (23,408) | (23,029) | (22,980)         | (23,206) | (23,057) | (23,624) | (24,002) | (163,306) |
| Non-Pay (exc Passthrough)                           | (7,268)  | (7,251)  | (7,945)          | (8,382)  | (8,108)  | (7,176)  | (8,254)  | (54,384)  |
| Passthrough costs                                   | (2,363)  | (2,829)  | ( <i>2,7</i> 35) | (3,028)  | (2,646)  | (2,658)  | (3,080)  | (19,339)  |
| Balance Sheet Write off                             |          |          | 1,200            |          |          |          |          | 1,200     |
| EBITDA  | (2,004)  | (554)    | 1,437            | (934)    | (1,862)  | 2,150    | (2,227)  | (3,994)   |
| Finance Costs                                       | (1,073)  | (1,140)  | (1,104)          | (1,109)  | (1,118)  | (1,093)  | (1,104)  | (7,741)   |
| Actual Deficit exc PSF                              | (3,077)  | (1,694)  | 333              | (2,043)  | (2,980)  | 1,057    | (3,331)  | (11,735)  |
| less Non Recurrent                                  |          |          |                  |          |          |          |          | 0         |
| Phased Income Adjustment                            |          |          | (1,600)          |          |          | (1,300)  | 500      | (2,400)   |
| Release of Deferred Income                          |          |          |                  |          |          | (125)    |          | (125)     |
| Release of HEE Deferred Income                      |          |          |                  |          |          | (290)    |          | (290)     |
| Readmission income                                  |          |          |                  |          |          | (1,480)  |          | (1,480)   |
| Maternity Incentivisation Scheme                    |          |          |                  |          |          | (512)    |          | (512)     |
| Cost of Organisational change                       |          |          |                  |          |          |          | 150      | 150       |
| Balance Sheet accrual release                       |          |          | (1,200)          |          |          |          |          | (1,200)   |
| Underlying Deficit                                  | (3,077)  | (1,694)  | (2,467)          | (2,043)  | (2,980)  | (2,650)  | (2,681)  | (17,592)  |
| Planned Deficit                                     | (2,770)  | (840)    | (1,294)          | (836)    | (517)    | (2,437)  | (132)    | (8,826)   |
| Variance  | (307)    | (854)    | (1,173)          | (1,207)  | (2,463)  | (213)    | (2,549)  | (8,766)   |



**Key Message** 

- The average underlying deficit in each of the first seven months in circa £2.5m, a cumulative position of £17.6m, £8.7m above planned levels.
- Income levels for individual months have been adjusted to reflect the actual income relating to the month once all activity has been coded.

• From month 7 the Trust will reverse phased income adjustment over the remainder of the year.

### **Income Analysis by Activity Type**

|                             | YTD<br>Budget | YTD<br>Actual | Variance | Variance % | YTD<br>Budget | YTD<br>Actual | Financial Variance<br>Value |
|-----------------------------|---------------|---------------|----------|------------|---------------|---------------|-----------------------------|
|                             | Activity      | Activity      | Activity |            | £000s         | £000s         | £000s                       |
| Accident and Emergency      | 75,897        | 78,548        | 2,651    | 3.4%       | 11,435        | 12,170        | 734                         |
| Outpatient Appts (Attend    | 254,655       | 252,289       | (2,366)  | (0.9%)     | 30,534        | 30,804        | 270                         |
| Elective Day Cases          | 30,494        | 30,298        | (196)    | (0.6%)     | 19,065        | 19,152        | 88                          |
| Elective Inpatient (Spells) | 3,049         | 3,277         | 228      | 7.0%       | 9,707         | 10,700        | 993                         |
| Non Elective (Spells)       | 34,400        | 35,317        | 917      | 2.6%       | 70,837        | 73,410        | 2,573                       |
| Non Elective Other          | 3,160         | 3,604         | 444      | 12.3%      | 6,600         | 7,578         | 978                         |
| Others (Inc Reserves)       |               |               |          |            | 72,730        | 78,021        | 5,291                       |
| Total                       | 401,655       | 403,333       | 1,678    | 0.4%       | 220,907       | 231,835       | 10,927                      |
| Provider Sustainability Fu  | nding (PSF)   |               |          |            | 8,444         | 8,444         | 0                           |
| Total after PSF             | 401,655       | 403,333       | 1,678    | 0.4%       | 229,351       | 240,279       | 10,927                      |

Accident and Emergency attendances are above planned levels by 3.4%, creating a positive variance to plan of £0.734m.

Outpatient attendances are under planned levels by 0.9%

Elective Inpatient spells are under delivering against plan by 228 spells with a positive variance of £993k Non Elective activity is 917 spells higher than the planned levels (2.6%); this includes the clinical decisions unit (CDU) at the PRH site. This has delivered a positive variance of £2.573m to plan. In the planning assumptions the Trust has assumed a circa 8% growth in non electives in comparison to 18/19 levels and this has been overachieved by a further 2.2%.

Blended tariff adjustment, the contract adjustment to income values for non elective and Accident and Emergency activity amounted to £4.055m Other includes the phased income adjustment from both local Health Economy CCGs of £2.4m and readmissions income of £1.480m and FIT monies of £.613m.

When compared to the signed CCG contract financial values , Shropshire CCG are over performing by £6.273m (7.3%) and Telford & Wrekin by £3.347m (5.7%)

This is mainly in non elective activity with over performance.

#### **Key Messages**

- Income over performance of £10.783m year to date. Non elective activity above plan by 2.2% and circa 10% higher than activity levels in 18/19.
- Receipt of phased income adjustment from local CCGs of £2.9m in Qtr1 and Qtr2. Readmissions income received from both CCG's of £1.480m.

# Income and Expenditure year to date and forecast outturn

|  | Annual       |           | YTD                      |           | Forecast     | Outturn (most       | : likely |          |                                |            |                |
|--|--------------|-----------|--------------------------|-----------|--------------|---------------------|----------|----------|--------------------------------|------------|----------------|
|  | NHSI Plan    | Plan      | Actual                   | Variance  | Plan         | scenario)<br>Actual | Variance |          |                                |            |                |
|  | £000s        | £000s     | £000s                    | £000s     | £000s        | £000s               | £000s    | Fore     | cast normalised income variand | e          |                |
|  |              |           |                          | 1         |              |                     |          |          |                                |            |                |
| Income   | 345,477      | 201,383   | 212,496                  | 11,113    | 345,477      | 356,930             | 11,453   |          | <b>r</b>                       | Income Var |                |
| Income for pass through costs (Excluded medicines and devices) | 33,382       | 19,525    | 19,339                   | (186)     | 33,382       | 33,063              | (319)    |          | ne Overperformance             | £000       | £000<br>11,453 |
| Pay  | (273,760)    | (157,753) | (163,306)                | (5,553)   | (273,760)    | (282,331)           | (8,571)  |          | alised Adjustments             |            | ,              |
| Non-Pay & Reserves   | (76,109)     | (45,207)  | (54,384)                 | (9,177)   | (76,109)     | (90,540)            | (14,431) |          | •                              |            |                |
| Non-pay pass through costs                                     | (33,382)     | (19,525)  | (19,339)                 | 186       | (33,382)     | (33,063)            | 319      |          | ne Phasing Adjustment          |            |                |
| Reserves   | 1,200        | 700       | 1,200                    | 500       | 1,200        | 1,200               | 0        | Readr    | nissions                       | (1,480)    |                |
| Total expenditure  | (382,051)    | (221,785) | (235,8 <mark>2</mark> 9) | (14,044)  | (382,051)    | (404,734)           | (22,683) | Defer    | red income                     | (415)      |                |
| EBITDA   | (3,192)      | (877)     | (3,994)                  | (3,117)   | (3,192)      | (14,741)            | (11,549) | Bowe     | I Screening Income             | (613)      |                |
| Finance Costs  | (14,159)     | (7,949)   | (7,741)                  | 208       | (14,159)     | (14,159)            | 0        | Total    | adjustments                    |            | (2,508)        |
| Surplus/(deficit) against Control Total pre Support            | (17,351)     | (8,826)   | (11,735)                 | (2,909)   | (17,351)     | (28,900)            | (11,549) | Norm     | alised Income overperformance  |            | 8,945          |
| Provider Support   | 17,351       | 8,444     | 8,444                    | 0         | 17,351       | 9,166               | (8,185)  |          |                                |            |                |
| Surplus/(deficit) against Control Total post PSF               | 0            | (382)     | (3,291)                  | (2,909)   | о            | (19,734)            | (19,734) |          |                                |            |                |
| Year to Date normalised income variance                        |              |           |                          |           |              |                     |          |          |                                |            |                |
| In   | come Varianc | e         |                          |           |              |                     |          |          |                                |            |                |
|  | £000 £       | 000 No    | rmalised                 | Income p  | osition at m | onth 7 is an        | over pe  | formance | of £6.205m versus an £8.9i     | n over     |                |
| Income Overperformance at Month 7                              | 11,          |           |                          | e at mont |              |                     |          |          |                                |            |                |
| Normalised Adjustments   | ,            |           |                          |           |              |                     |          |          |                                |            |                |
| •  | 2,400)       |           |                          |           |              |                     |          |          |                                |            |                |

| Normalised Income overperformance |         | 6,205   |
|-----------------------------------|---------|---------|
| Total adjustments                 | _       | (4,908) |
| Bowel Screening Income            | (613)   |         |
| Deferred income                   | (415)   |         |
| Readmissions (full year effect)   | (1,480) |         |
| Income Phasing Adjustment         | (2,400) |         |

Make It **Happen** We Value **Respect** Together We **Achieve** 

### **CIP Delivery**

|                        | Ye           | ear to Date    | 2                |   | Fore         | rn             |                  |
|------------------------|--------------|----------------|------------------|---|--------------|----------------|------------------|
| CIP Programme          | Plan<br>£000 | Actual<br>£000 | Variance<br>£000 | - | Plan<br>£000 | Actual<br>£000 | Variance<br>£000 |
|                        |              |                |                  |   |              |                |                  |
| Internal Core CIP plan | 7,115        | 2,062          | (5,053)          |   | 12,901       | 8,000          | (4,901)          |
| Breakeven schemes      | 3,400        | 3,770          | 370              |   | 5,988        | 5,837          | (150)            |
| Total                  | 10,515       | 5,832          | (4,683)          |   | 18,889       | 13,837         | (5,051)          |

The Trust has delivered £5.83M CIP as at Month 7. This is made up of:


- Core CIPs have delivered £2.06M YTD against the NHSI submitted plan of £7.12M (29%).
- Break-even schemes have delivered £3.77M YTD against a plan of £3.40M (111%).
- As a result, the overall YTD CIP position is £5.83M delivered against an overall YTD Plan (Core + Breakeven) of £10.52M (55% of YTD delivery).

Assumed outturn CIP delivery within the 'most likely' scenario of forecast outturn is £8.0m, and full delivery of the breakeven schemes.

Currently the report to the financial improvement board illustrates that for the core CIP schemes,  $\pm 5.223$ m of the  $\pm 8.0$ m required in the forecast have been fully identified. Further schemes to a level of  $\pm 2$ m have been identified and currently within the pipeline schemes for delivery.




### Pay 2019/20



#### **Key Messages**

- At the end of October the pay budget is overspend by £6.3m as a result of an overspend on agency costs of £4.2m and non delivery of CIP of £1.5m. Substantive staff costs have increased by £0.3m in October over that incurred in September. The operationalisation of the ED nursing business case continues to be a financial concern. The increasing reliance on agency is creating financial pressures. The Trust continues to spend on average £1m per month on agency that recorded for the previous year.
- The overall run rate for October is £0.4m higher than September. September figures also include the impact of an element of double running costs whilst newly recruited RNs are introduced into the organisation.
- The Trust alongside Deloitte have weekly panels to review the key staff groups using agency to improve the review and improve recruitment and other aspects with the intention of reducing usage.

# **Agency Expenditure 2019/20**



| Ann               | ual                    |                           |                     | YTD                             |   |   |                     | In Month                        |   |
|-------------------|------------------------|---------------------------|---------------------|---------------------------------|---|---|---------------------|---------------------------------|---|
| Agency<br>Ceiling | NHSI<br>Agency<br>Plan | Agency<br>Ceiling<br>Plan | Agency<br>NHSI Plan | Agency<br>Expenditure<br>Actual | Variance<br>Under/<br>(Over)<br>Agency<br>Ceiling | Variance<br>Under/<br>(Over)<br>Agency<br>NHSI Plan | Agency<br>NHSI Plan | Agency<br>Expenditure<br>Actual | Variance<br>Under/<br>(Over)<br>Agency<br>NHSI Plan |
| £000s             | £000s                  | £000s                     | £000s               | £000s                           | £000s   | £000s   | £000s               | £000s                           | £000s   |
| 14,232            | 19,153                 | 8,302                     | 10,980              | 15,189                          | (6,887)   | (4,209)   | 1,566               | 2,428                           | (862)   |

#### **Agency Spend by Staff Group**


#### Key Messages

• Agency expenditure has exceeded budget by £0.862m in month, £4.209m year to date. associated with unavailability and capacity issues.



- Expenditure in October is £1m more in the month than the average for 2018/19.
- Annual plan for agency is £19.2m with an nationally set agency ceiling of £14.2m.
   The Trust is currently exceeding the agency ceiling by 83%. Within the use of resc
  - The Trust is currently exceeding the agency ceiling by 83%. Within the use of resources metrics an actual spend greater than 50% of the ceiling value results in an 'inadequate' score against the metric.

### **Non Pay**



#### Key Messages

- Month 7 non pay spend excluding high costs drugs and devices amounted to £8.255m and £54.387m year to date.
- September's non-pay was positively impacted by £0.5m CNST Maternity Incentivisation Scheme benefit.



### Cash

|   | Actual<br>YTD | Total Based<br>on Revised |     |         |            |        |     |                         |                            |          |            |        |         |         |          |
|---|---------------|---------------------------|-----|---------|------------|--------|-----|-------------------------|----------------------------|----------|------------|--------|---------|---------|----------|
|   |               | Forecast                  |     |         |            |        | 201 | 9/20 Ca                 | ash Posi                   | tion an  | d Fore     | ecast  |         |         |          |
|   | £000's        | £000's                    |     | _       |            |        |     |                         |                            |          |            |        |         |         |          |
| Balance B/fwd   | 1,649         | 1,649                     | 2   | 0       |            |        |     |                         |                            |          |            |        |         |         |          |
| I&E CASHFLOW  |               |                           | 1   | 5       |            |        |     |                         |                            |          |            |        |         |         |          |
| Income I&E (inc Donated & PSF)  | 227,218       | 400,220                   | -   |         |            |        |     |                         |                            |          |            |        |         |         |          |
| Pay I&E   | (163,835)     | (282,331)                 | 1   | 0       |            |        | ~   |                         |                            |          |            |        |         |         |          |
| Non Pay I&E   | (70,347)      | (122,403)                 | I . | 5       |            |        |     |                         |                            | _        |            |        |         |         |          |
| Finance Costs I&E   | (1,619)       | (3,602)                   |     |         |            |        |     |                         |                            |          |            | $\sim$ |         |         |          |
| Capital Expenditure (inc Donated) re Depreciation   | (2,689)       | (11,618)                  | Ems | o 🕂 🗖   |            |        |     |                         |                            |          | _          |        |         | <hr/>   |          |
| Total I&E Cashflow  | (11,271)      | (19,734)                  |     |         |            |        |     |                         |                            |          |            |        |         |         |          |
|   |               |                           | -!  | 5       |            |        |     |                         |                            |          |            |        |         | -       |          |
| EXTERNAL FUNDING  |               |                           | -10 |         |            |        |     |                         |                            |          |            |        |         |         |          |
| PDC Allocations - (Expenditure)   | (442)         | (11,796)                  | -10 |         |            |        |     |                         |                            |          |            |        |         |         |          |
| PDC Allocations - (Income)  | 0             | 11,796                    | -1  | 5       |            |        |     |                         |                            |          |            |        |         |         | <b>`</b> |
| Total External Funding Cashflow   | (442)         | 0                         |     | _       |            |        |     |                         |                            |          |            |        |         |         |          |
|   |               |                           | -20 |         | •          | •      | •   | •                       | •                          | •        | •          | •      | 0       |         |          |
| Total Balance Sheet Changes   | 12,544        | 4,458                     |     | Apr-19  | May-19     | Jun-19 | -10 | Aug-19                  | Sep-19                     | -10      | -19        | -16    | Jan-20  | Feb-20  | Mar-20   |
| Total Cashflow  | 832           | (15,276)                  |     | Apr     | 1ay        | Inn    | Jul | Зu                      | Sep                        | Oct      | Nov<br>Nov | Dec    | Jan     | eb      | /lar     |
| Balance C/fwd   | 2,481         | (13,627)                  |     |         | 2          | ,      |     | 4                       | 0,                         | 0        | 2          |        |         | -       | 2        |
|   |               |                           |     |         |            |        |     |                         |                            |          |            |        |         |         |          |
| Required Cash Support   | 0             | 15,327                    |     | Cash M  | onth End   |        | _   | 201                     | 9/20 Pla                   | n        |            |        | Project | ion nre | support  |
| Balance C/fwd after Support   | 0             | 1,700                     |     | Custin  | ontin Linu |        |     | 201                     | <i>5<sub>1</sub>2</i> 011a |          |            |        | rioject | ion pre | Support  |
| Cash Support included Nov & Dec in lieu of PSF<br>& FRF (to be repaid on receipt of income) |               | 5,922                     |     | Average | e Daily Ca | sh YTD |     | <ul> <li>Low</li> </ul> | est Daily                  | / Cash Y | ΓD         |        |         |         |          |

#### **Key Messages**

- If the Trust achieves the planned breakeven position, it will be eligible for funding totalling £12.593m in respect of conditional PSF/FRF funding. It is projected that the minimum cash balance of £1.700m will be achieved.
- However if the Trust does not achieve financial plan, PSF and FRF funding will not be received for Quarters 3 and 4 resulting in shortfall in income of • £8.138m.
- The above projected cashflow is based on the revised forecast projection of deficit of £19.734m, with cash benefit in 2019/20 in respect of receipt of PSF funding relating to 2018/19 (£4.5m)
- It is projected that the Trust will require external cash support of £15.327m. •
- The Trust will receive cash support in lieu of conditional funding of £2.520m in November and has requested £3.402m to be received in December. This support is included in the above. This is repayable on receipt of conditional income funding.

### **Capital Programme**

|   |  | ( |
|---|--|---|
| The Shrewsbury and Telford Hospital NHS Trust |  |   |
|   |  |   |

| 2019/20 Capital Programme Update as at Month 07 (October 2019)                |                    |        |                            |                              |                      |                     |          |                  |
|---|--------------------|--------|----------------------------|------------------------------|----------------------|---------------------|----------|------------------|
|   |                    |        |                            | Total                        | Expenditure          |                     |          | Variance         |
|   | 2019/20<br>Capital |        | Expenditure<br>committed - | expenditure/<br>committed to | committed -<br>to be | Scheme yet<br>to be | Forecast | under/<br>(over) |
| Scheme  | Budget             | date   | ordered                    | date                         | ordered              | identified          | Outturn  | spend            |
|   | £000's             | £000's | £000's                     | £000's                       | £000's               | £000's              | £000's   | £000's           |
| Outstanding Commitments from 2018/19  | 200                | -5     | 10                         | 5                            | 180                  | 2                   | 186      | 14               |
| PC In House costs of delivery of schemes                                      | 780                | 443    | 338                        | 781                          | 0                    | 0                   | 781      | -1               |
| PC RSH MLU/PAU - P2 FCHS  | 0                  | 0      | 0                          | 0                            | 0                    | 0                   | 0        | 0                |
| PC Fire safety Programme  | 291                | 4      | 9                          | 13                           | 278                  | 0                   | 291      | 0                |
| PC Subway Duct - RSH (further phases following on from 2017/18 agreement)     | 950                | 0      | 33                         | 33                           | 917                  | 0                   | 950      | 0                |
| PC Ophthalmology move into Copthorne Building - Phase 3 (additional asbestos) | 50                 | 0      | 2                          | 2                            | 48                   | 0                   | 50       | 0                |
| PC IT Storage Solution (further phases following on from 2018/19 investment)  | 500                | 467    | 0                          | 467                          | 33                   | 0                   | 500      | 0                |
| PC Replacement of Autoclaves in Path Lab (agreed at CPG)                      | 202                | 0      | 5                          | 5                            | 197                  | 0                   | 202      | 0                |
| PC RSH Catering Service (agreed at CPG/PC)                                    | 68                 | 10     | 21                         | 31                           | 37                   | 0                   | 68       | 0                |
| PC Eye Injection Automation System (agreed at CPG)                            | 80                 | 0      | 0                          | 0                            | 80                   | 0                   | 80       | 0                |
| Total Delegated Contingency Funds   | 1,300              | 382    | 156                        | 539                          | 10                   | 751                 | 1,300    | 0                |
| Corporate Contingency (In Year Allocations)                                   | 1,170              | 237    | 110                        | 348                          | 699                  | 152                 | 1,198    | -28              |
| Capitalisation of Expenditure   | 1,200              | 690    | 318                        | 1,008                        | 192                  | 0                   | 1,200    | 0                |
| Additional Capitalisation of Expenditure - FIT funding                        | 619                | 0      | 619                        | 619                          | 0                    | 0                   | 619      | 0                |
| AS Endoscopy Suite Reconfiguration  | 1,300              | 0      | 0                          | 0                            | 1,300                | 0                   | 1,300    | 0                |
| RF Fire Safety Copthorne Building (original balance)                          | 359                | 228    | 21                         | 249                          | 110                  | 0                   | 359      | 0                |
| Uncommitted Fund Balance  | 749                | 0      | 0                          | 0                            | 0                    | 749                 | 749      | 0                |
| UF High Value Radiology Equipment (inc PRH CT Scanner)                        | 400                | 1      | 349                        | 350                          | 50                   | 0                   | 400      | 0                |
| UF Sustainable Services   | 400                | 116    | 175                        | 292                          | 108                  | 0                   | 400      | 0                |
| UF Actions from CQC visit   | 10                 | 7      | 0                          | 7                            | 0                    | 3                   | 10       | 0                |
| UF Data Warehouse   | 441                | 37     | 417                        | 454                          | 0                    | 0                   | 454      | -13              |
| IGDA - A&E System - System C  | 900                | 0      | 0                          | 0                            | 900                  | 0                   | 900      | 0                |
| Total Internally Generated Capital Schemes                                    | 11,969             | 2,618  | 2,582                      | 5,200                        | 5,140                | 1,657               | 11,997   | -28              |
| NIY Sustainable Services Project  | 4,674              | 408    | 218                        | 626                          | 4,048                | 0                   | 4,674    | 0                |
| NIY - Fire Safety Copthorne Building  | 1,622              | 2      | 346                        | 348                          | 1,246                | 0                   | 1,594    | 28               |
| NIY - Additional Capacity - RSH/PRH   | 1,500              | 0      | 343                        | 343                          | 1,157                | 0                   | 1,500    | 0                |
| NIY - PRH Modular Build/Refurbishment of Wrekin MLU                           | 4,000              | 32     | 3,388                      | 3,420                        | 580                  | 0                   | 4,000    | 0                |
| Overcommitted   | -351               | 0      | 0                          | 0                            | 0                    | -351                | -351     | 0                |
| Total Capital Programme   | 23,414             | 3,060  | 6,877                      | 9,937                        | 12,171               | 1,306               | 23,414   | 0                |
| % Internally Generated  |                    | 22.54% | 22.22%                     | 44.76%                       | 44.24%               | 14.02%              | 103.02%  |                  |
| % Total Capital Programme   |                    | 13.07% | 29.37%                     | 42.44%                       | 51.98%               | 5.58%               | 100.00%  |                  |



Make It **Happen** We Value **Respect** 

Together We Achieve


|  | Internally<br>CF |         | Total CRL |         |  |  |
|--|------------------|---------|-----------|---------|--|--|
|  | £m               | %       | £m        | %       |  |  |
| Expensed                               | 2.618            | 22.54%  | 3.060     | 13.07%  |  |  |
| Ordered – not ye<br>expensed           | t 2.582          | 22.22%  | 6.877     | 29.37%  |  |  |
| Committed – not ye ordered or expensed | t 5.140          | 44.24%  | 12.171    | 51.98%  |  |  |
| To be identified/<br>overcommitted     | 1.629            | 14.02%  | 1.306     | 5.58%   |  |  |
|  | 11.969           | 103.02% | 23.414    | 100.00% |  |  |

#### Key Messages

- The total (purchased and donated) Internally Generated Capital Resource Limit (CRL) for 2019/20 is now £11.618 m.
- At Month 07, only £1.657m remains uncommitted

   £0.152m in Corporate Contingency; £0.751m
   within the delegated reserve fund; £0.749m within
   the general uncommitted reserve and £0.005m yet
   to be committed in agreed schemes.
- The Trust is currently £0.351m overcommitted (after allocation for FIT equipment) whilst awaiting confirmation of receipt of £0.441m funding from HSLI funding for Data Warehouse. (Business case to be submitted in November) The formal application is currently being finalised.
- Trust has received confirmation of success of emergency capital loan funding £1.622m for fire safety in the Copthorne building.
- The Trust has been successful in receiving additional capital funding of £5.5m for additional capacity (£4.0m Modular Building at PRH and £1.5m for additional beds at RSH & PRH) as reported at last Board meeting).

### **Receivables/Payables**



|                                       | 1-30 Days | 31-60 Days | 61+ Days | Total |
|---------------------------------------|-----------|------------|----------|-------|
|                                       | £000s     | £000s      | £000s    | £000s |
| NHS England Commissioning             | 900       | -25        | 400      | 1,275 |
| Telford & Wrekin CCG                  | 939       | 108        | 541      | 1,588 |
| Powys LHB                             | 27        | 27         | 527      | 581   |
| RJAH NHSFT                            | 158       | 42         | 125      | 325   |
| Shropshire CCG                        | 2,721     | 88         | 173      | 2,982 |
| CP Plus                               | 124       | 124        | 0        | 248   |
| Shropshire Community Health Trust     | 113       | 17         | 27       | 157   |
| University Hospital of North Midlands | 75        | 0          | 27       | 102   |

The outstanding receivables balances as at 31 October 2019 over £0.100m are:

The 1-30 days balance with NHS England Commissioning includes £642k of invoices raised in advance for Month 8 contract income to ensure these invoices are paid in November 2019.


NHSE dental contract for Month 6 was not paid in Month 6 due to the commissioner being unable to authorise the invoices on time. This invoice has been paid in November 2019.

Shropshire CCG (£30k per month) and Telford and Wrekin CCG (£108k per month) are short-falling their monthly contract payments due to contract disputes.

Powys LHB includes an invoice raised for £431k for the final contract settlement for 2018/19. This invoice has been agreed for payment in November 2019.

There were no credit notes raised over £0.100m in October 2019.





# **Commissioner 2019/20 Contract Update**

| Commissioner   | Value        | Agreed       | Signed*      | Update  |
|--|--------------|--------------|--------------|---|
| Main CCG - Shropshire, Telford and Associates including CQUIN        | £254,784,328 | $\checkmark$ | $\checkmark$ |   |
| NHS England – Specialised Services and<br>Associates including CQUIN | £54,122,168  | $\checkmark$ | $\checkmark$ |   |
| Powys Teaching Health Board  | £26,699,210  | ×            | ×            | Issue of Welsh Commissioners paying English<br>19/20 National Tariff (less 1.25% CQUIN) has<br>been resolved. Revised offers have been<br>issued. |
| Betsi Cadwaladr University Health Board (North<br>Wales)             | £1,682,113   | ×            | ×            | Issue of Welsh Commissioners paying English<br>19/20 National Tariff (less 1.25% CQUIN) has<br>been resolved. Revised offers have been<br>issued. |
| Welsh Health Specialised Services Committee<br>(WHSSC)               | £1,092,802   | ×            | ×            | Issue of Welsh Commissioners paying English<br>19/20 National Tariff (less 1.25% CQUIN) has<br>been resolved. Revised offers have been<br>issued. |
| Hywel Dda  | £139,318     | ×            | ×            | Issue of Welsh Commissioners paying English<br>19/20 National Tariff (less 1.25% CQUIN) has<br>been resolved. Revised offers have been<br>issued. |

If our Welsh commissioners only funded estimated activity levels at 2018/19 tariff prices (i.e. a worst case scenario) there would be a shortfall in income of circa £1.3m. The NHSE national pricing team have confirmed Sath will be paid the 1.25% CQUIN directly via NHSE and we will shortly be requesting some info to enable the national team to validate payment values. We will retain this as an income risk until the final payment is received, but the likelihood of non payment has been significantly reduced.

